- Home
- News
- solomon islands
- heart function
Refine by
Heart Function Articles & Analysis
34 news found
MADRID, Spain – April, 2026 — Corify Care today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the ACORYS® System, the first imageless, non-invasive cardiac mapping platform capable of delivering a global, four-chamber view of cardiac electrical activity in real time.The milestone represents a fundamental shift in electrophysiology by combining ...
Bodyport, a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, announced today the appointment of Jim Pursley to the company’s board of directors. “I am excited to join the Bodyport Board of Directors as they reimagine care for patients living with complex chronic conditions. Bodyport’s focus on the patient has driven them to ...
Bodyport, a digital therapeutics company on a mission to address complex chronic conditions, announced today that its noninvasive biomarker platform, the Bodyport Cardiac Scale™ received U.S. Food & Drug Administration (FDA) 510(k) clearance. This innovative solution enables people with fluid management conditions, such as heart failure and kidney disease, to noninvasively assess ...
Bodyport, a medtech company based in San Francisco, developed the Bodyport Cardiac Scale, a set of weighing scales that can non-invasively assess fluid status and heart function. The scales can detect these signals through the feet when a patient steps onto the device. The technology is intended to be convenient and requires only 20 seconds each morning, and should easily lend itself to ...
DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart failure patients with dramatic and durable improvements in ...
Santa Clara, Calif.– July 12, 2022 – Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the AccuCinch® Ventricular Restoration System. Currently being evaluated in the CORCINCH-HF pivotal clinical trial, the AccuCinch System ...
Bodyport, a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, today announced the appointment of medtech industry veteran, John Lipman, as Chief Executive Officer. Bodyport co-founder, Corey Centen, will continue as President and also serve as Chief Technology Officer (CTO) of the company. Lipman’s appointment comes as Bodyport prepares for ...
MINNEAPOLIS, MAY 9,2022 - CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), developer of the world's first FDA-approved neuromodulation device to treat the symptoms of heart failure, has received U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR) conditional labeling for its Barostim System. The Barostim System now includes instructions to allow for safe MRI scans of the head and ...
ByCVRx
BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CardiAMP® Cell Therapy System for the treatment of heart failure. It is believed to be the first cardiac cell therapy to ...
EchoNous, the leader in ultra-portable, AI-guided point-of-care ultrasound (POCUS) tools and software, announced that the company has partnered with Singapore-based Us2.ai, developers of machine learning-driven software that automates the analyses of echocardiographic imagery and measurements. Us2.ai’s technology received FDA approval on July 27, 2021 Us2.ai’s software is being ...
Xeltis, a clinical-stage company with the most advanced polymer-based restorative cardiovascular devices, today announced that it has started the first-ever pivotal trial for a synthetic restorative pulmonary valve. To date, pediatric patients requiring right ventricular outflow tract (RVOT) reconstruction have been successfully implanted as part of the global, FDA-approved Xplore2/Pivotal study. ...
MILPITAS, Calif. – April 22, 2021 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany. The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel ...
2,400-Patient Trial Utilizes Globally-Respected SWEDEHEART Registry Database in Randomized Study of First Metallic Device Treating Coronary Artery Disease That Adapts to Vessel Physiology MILPITAS, Calif. – March 16, 2021 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced commencement of the INFINITY-SWEDEHEART randomized ...
Berlin, March 2021: With the first-in-man implantation of the Berlin Heart Venous Cannula at the LMU University Hospital Munich (Grosshadern), Germany, Berlin Heart offers patients with a failing Fontan circulation a unique chance to survive the waiting time for a donor heart. These patients are in a life-threatening condition: their health has deteriorated so much that they desperately need a ...
BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter based Ventricular Restoration (TCVR), today announced that the German Institute for Hospital Remuneration (InEK) has renewed the NUB Status 1 reimbursement designation in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System used in LIVE™ ...
International Trial to Compare Bioadaptor, a Novel Coronary Artery Implant Designed to Adapt to Vessel Physiology, with Traditional Drug Eluting Stents International Trial to Compare Bioadaptor, a MILPITAS, Calif. – January 13, 2020 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the first patient has been treated ...
BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that heart failure specialist Jerry Estep, MD, of the Cleveland Clinic has been appointed co-principal investigator of the pivotal ALIVE Trial studying LIVE Therapy using the Revivent TC TransCatheter Ventricular ...
The British Occupational Hygiene Society, a scientific charity and the Chartered Society for Workplace Health Protection, is welcoming research published by Imperial College London’s DEMist project, which uses black carbon to track exposure of professional drivers to diesel exhaust. The study led by Dr Ian Mudway, Senior Lecturer at the MRC Centre for Environment and Health, Environmental ...
BOHS welcomes new research by IOSH-sponsored Imperial College into occupational exposure to diesel for professional drivers, but cautions that it highlights a COVID-19 dilemma with ventilation. The British Occupational Hygiene Society, a scientific charity and the Chartered Society for Workplace Health Protection, is welcoming research published by Imperial College London’s ...
Hanover, Germany, October 22, 2020 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company, focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced a publication in the European Heart Journal (doi:10.1093/eurheartj/ehaa791) demonstrating that repeated treatment with its lead compound CDR132L is safe, improves cardiac ...